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The capsid proteins VP2 and VP3 of infectious bursal disease virus, a birnavirus, are derived from the
processing of a large polyprotein: NH2-pVP2-VP4-VP3-COOH. Although the primary cleavage sites at the
pVP2-VP4 and VP4-VP3 junctions have been identified, the proteolytic cascade involved in the processing of
this polyprotein is not yet fully understood, particularly the maturation of pVP2. By using different approaches,
we showed that the processing of pVP2 (residues 1 to 512) generated VP2 and four small peptides (residues 442
to 487, 488 to 494, 495 to 501, and 502 to 512). We also showed that in addition to VP2, at least three of these
peptides (residues 442 to 487, 488 to 494, and 502 to 512) were associated with the viral particles. The
importance of the small peptides in the virus cycle was assessed by reverse genetics. Our results showed that
the mutants lacking the two smaller peptides were viable, although the virus growth was affected. In contrast,
deletions of the domain 442 to 487 or 502 to 512 did not allow virus recovery. Several amino acids of the peptide
502 to 512 appeared essential for virus viability. Substitutions of the P1 and/or P1 position were engineered
at each of the cleavage sites (P1-P1: 441–442, 487–488, 494–495, 501–502, and 512–513). Most substitutions
at the pVP2-VP4 junction (512–513) and at the final VP2 maturation cleavage site (441–442) were lethal.
Mutations of intermediate cleavage sites (487–488, 494–495, and 501–502) led to viable viruses showing
different but efficient pVP2 processing. Our data suggested that while peptides 488 to 494 and 495 to 501 play an
accessory role, peptides 442 to 487 and 502 to 512 have an unknown but important function within the virus cycle.
The birnaviruses are a family of small icosahedral viruses
infecting insects, fish, and birds (15). Only five proteins, gen-
erally referred to as VP1, VP2, VP3, VP4, and VP5, are en-
coded by the viral genome. The T13 icosahedral birnavirus
capsids are made by the VP2 and VP3 proteins. They contain
the two double-stranded RNA genomic segments (A and B)
and the VP1 protein, a putative RNA-dependent RNA poly-
merase. Translation of genomic segment A yields a polypro-
tein, pVP2-VP4-VP3, and a small protein, VP5, of unknown
function. The B segment encodes VP1. The polyprotein pro-
cessing gives rise to VP4, the viral protease, and VP2 and VP3.
VP2 carries all the neutralizing epitopes, suggesting that it is at
least partly exposed at the outer surface of the capsid. VP3,
which interacts with VP1 (16, 24), is thought to be located on
the inner surface of the capsid (6). VP3 contains charged
residues at its carboxy-terminal domain, a domain suggested to
be involved in the genomic RNA interaction. As found for
other virus families, the capsid assembly seems to be regulated
by polyprotein processing.
The infectious bursal disease virus (IBDV), an avian birna-
virus, is of major importance to the poultry industry. It causes
an immunosuppressive disease in young chickens. After infec-
tion, IBDV multiplies rapidly in the B lymphocytes of the bursa
of Fabricius, leading to increased susceptibility to other dis-
eases. Very virulent strains have resulted in high rates of mor-
tality in many countries.
The first step governing the IBDV capsid assembly is the
autoproteolytic cleavage of the polyprotein (1,012 amino ac-
ids). This process generates pVP2, VP4, and VP3. The pVP2-
to-VP2 conversion involves several proteolytic cleavages at the
carboxy end of pVP2 (1, 14, 20). Based on mutagenesis studies,
the putative cleavage site was proposed as defined by the (Thr/
Ala)-X-Ala2Ala motif; three potential sites are present in the
C-terminal domain of pVP2 (14).
In the present study, we further analyzed the maturation
process of VP2. By using mass spectrometry and N-terminal
sequence analysis, we showed that VP2 and three (most prob-
ably four) peptides derived from the pVP2 are associated with
the virus particle. These results confirmed the presence of the
three cleavage sites previously proposed (14). To analyze the
importance of these peptides to the virus cycle, we developed
a reverse genetic system similar to the one previously described
(5), based on a self-processing ribozyme cassette (7). We
showed that the two 7-amino-acid long peptides are not essen-
tial for virus viability, in contrast to the two peptides located at
the ends of the domain characteristic of pVP2. These essential
peptides are likely to play an important role in the virus cycle.
MATERIALS AND METHODS
Virus purification. A 100-ml volume of supernatants of IBDV strain CT-
infected chicken embryo fibroblasts was ultracentrifugated at 40,000 rpm for 1 h
in a 45Ti rotor (Beckman) at 4°C. The pellets were resuspended in 10 mM Tris
(pH 7.4)–100 mM NaCl–1 mM EDTA and then treated with Freon 113 for
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purification by density gradient centrifugation in CsCl with a density of 1.33.
Ultracentrifugation was carried out overnight at 35,000 rpm in an SW55 rotor
(Beckman) at 4°C. The bands were collected and stored at 4°C.
Gel electrophoresis. To analyze large peptides, sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) (16% acrylamide) was performed
using a Mini-Protean II system (Bio-Rad, Paris, France) by the method of
Schägger and von Jagow (21) with modifications (19). LMW and PMW calibra-
tion kits (Pharmacia) were used as molecular weight standards, and the proteins
were stained with Serva blue G. To analyze proteins, aliquots were subjected to
SDS-PAGE (10% acrylamide) (13) and the gels were dried and exposed for
autoradiography.
Protein labeling and immunoprecipitation. In vitro, polymerase T7-driven
expression was carried out using the TNT Quick-Coupled transcription-transla-
tion system (Promega) as described by the manufacturer, except that the reac-
tions were performed in a final volume of 11 l. The DNA template (1 g) was
incubated for 1 h at 30°C. After incubation, aliquots of 2 to 3 l were subjected
to gel electrophoresis. In cell culture, 2  106 LSCC-BK3 cells were infected with
150 l of supernatant of cells infected for 5 days. At 18 h postinfection, the cells
were resuspended in 1.5 ml of medium-10 l of Promix (Amersham). At 6 h
later, the cell supernatants were half-diluted in RIPA buffer (50mM Tris [pH 8],
150 mM NaCl, 2% Triton X-100) and the cells were resuspended in 1 ml of the
same buffer. After clarification by centrifugation, the cell or supernatant extracts
were processed for immunoprecipitation. Extracts were incubated for 2 h at
room temperature with 1 l of undiluted hybridoma ascites fluid and 35 l of a
1:1 slurry of protein A-Sepharose 4B (Pharmacia) under gentle agitation. The
beads were washed four times with 1 ml of RIPA buffer, treated for 2 min at
100°C in Laemmli denaturing buffer plus 5% 2-mercaptoethanol, and centrifu-
gated. The resulting supernatants were subjected to electrophoresis.
Amino acid sequence analysis. The virus purified by CsCl density centrifuga-
tion (140 l of 2.7 M CsCl) was diluted 10-fold with water and then adsorbed on
a Prosorb device (polyvinylidene difluoride [PVDF] membrane) by low-speed
centrifugation (500  g at 15°C) in Hettich 16R (flow rate, 20 l/min). Mem-
brane washes were carried out with 10% methanol in water. For large peptides,
electrophoretic samples were transferred onto the PVDF membrane by passive
absorption as described previously (L. R. Zieske, S. Masiaiarz, S. Chamberlain,
and J. McGovern, Bioinformatics Biomol. Technol: Linking Genomes Pro-
teomes Biochem., poster, 1999). After the destaining step, the band of interest
was excised and dried in a Speed-Vac for 30 min, and the gel piece was reswollen
in 50 l of 2% SDS in 0.2 M Tris-HCl (pH 8.5) for 30 min. After swelling, 200
l of high-pressure liquid chromatography (HPLC) water was added and then a
piece of prewet (methanol) PVDF membrane (4 by 4 mm [Problott]) was added
to the solution. The procedure required 2 days at room temperature (23°C) with
gentle vortexing. At the end of this transfer time, the gel piece and the solution
were clear and the membrane was blue. The membrane was washed five times
with 1 ml of 10% methanol with vortexing. After drying, the membranes were
placed in the cartridge of the Perkin-Elmer Procise 494 HT protein sequencer.
N-terminal amino acid sequence analyses were performed by automated Edman
chemistry with methods and reagents recommended by the manufacturer.
Reversed-phase liquid chromatography of peptides. The virus purified by CsCl
density centrifugation (140 l), desalted twice on Sephadex G-25, and dried in a
Speed-Vac was extracted with 4 l of 5% formic acid–10% acetonitrile in water
for 2 h and diluted to 20 l with solvent A (0.1% [vol/vol] Fluka formic acid and
4 mM Fluka ammonium acetate in Merck HPLC water). Reversed-phase liquid
chromatography was run with an Applied Biosystems device (pump 140D and
UV detector 785 with U-shaped fused silica tubing; 7-mm path length) on a C4
LC-Packings capillary column (0.3 by 150 mm; porosity, 300 Å) at a controlled
temperature (40°C). The gradient was made by mixing solvent A with solvent B
(90% Perkin-Elmer acetonitrile, 0.1% [vol/vol] Fluka formic acid, and 4 mM
Fluka ammonium acetate in Merck HPLC water) at a flow rate of 4 l/min. The
acetonitrile gradient began at 4.5% and increased linearly to 85.5% in 90 min.
After being monitored for absorbance at 215 nm, the flow was split between 0.67
l/min for matrix-assisted laser desorption ionization (MALDI) interplate col-
lection and 3.33 l/min for manual collection.
Mass spectrometry analysis. A 4-l volume 50% (vol/vol) acetonitrile–0.3%
(vol/vol) trifluoroacetic acid was added to the dry sample, and the solution was
vortexed for 10 min. Next, the sample was desalted on ZipTip C4 (Millipore) and
eluted with 0.5 l of 70% (vol/vol) acetonitrile–0.3% (vol/vol) trifluoroacetic
acid. The sample was directly spotted onto the MALDI plate and dried at room
temperature, and then 0.5 l of -cyano-4-hydroxycinnamic acid (-CHCA; 3
mg/ml) in 50% (vol/vol) acetonitrile–0.1% (vol/vol) trifluororacetic acid was
added. Mass spectra were acquired on a Voyager-DE-STR time-of-flight mass
spectrometer (Applied Biosystems, Framingham, Mass.) equipped with a nitro-
gen laser emitting at   337 nm (Laser Science, Franklin, Mass.). The accel-
erating voltage used was 20 kV. All spectra were recorded in the positive reflec-
tor mode with a delayed extraction of 130 ns and a 62% grid voltage. The spectra
were calibrated using an external calibration: Des-Arg bradykinin, (M  H) 
904.4681 Da; angiotensin, (M  H)  1296.6853 Da; neurotensin, (M  H)
 1672.9175 Da; melittin, (M  H)  2845.762 Da, and bovine insulin B chain,
(M  H)  3494.6513 Da.
Construction of pT7-A-HDR. The complete genomic segment A of the Gum-
boral IBDV vaccine strain CT (Mérial, Lyon, France) was amplified by reverse
transcriptase PCR and cloned into pUC19 using the EcoRI restriction site to
generate pUC-IBDA as previously described (14). Thus, the 5 terminus of the
IBDA segment (GGATACGATCG. . .) was placed just downstream of the T7
promoter. The pUC-IBDA plasmid was digested with BsrGT and treated with
mung bean nuclease to generate a blunt end just at the 3 end of the IBDA
segment. A plasmid carrying the hepatitis delta virus antigenomic ribozyme and
the terminator T7 sequence was previously constructed (2), digested with SmaI
and EcoRV for excision of the insert, and subcloned into the pUC-IBDA plasmid
at the blunted BsrGI position. DNA sequencing revealed the unexpected codon
AAG at position 841 of the polyprotein gene, which was modified to GAG by
homologous substitution of an independent SacII-BglII IBDA segment (nucle-
otides 1756 to 3019). Sequence analysis was carried out to confirm the sequence
of the exchanged segment. The resulting plasmid was named pT7-A-HDR.
Construction of pT7-B-HDR. The complete IBDB segment of the CT strain was
amplified by reverse transcriptase PCR with oligonucleotides 5-AGAGAATTCTA
ATACGACTCACTATAGGATACGATGGGTCTGACCCTCT and 5-GATGA
ATTCTGCAGCCCGGGGGCCCCCGCAGGCGAAGGCC and cloned into the
EcoRI site of pUC19. Next, the pBluescript II SK() phagemid (Stratagene) was
cut with SspI and HincII and self-ligated to delete the T7 promoter (plasmid
SK	). The pUC-IBDB plasmid was digested with PstI and EcoRI, and the insert
was cloned into SK	. SK	-IBDB was cut with SmaI for blunt-end ligation with
the ribozyme terminator DNA segment excised SmaI-EcoRV. The complete
sequencing of the insert was carried out, and an unexpected codon CCA was
identified at position 773 of VP1. Codon 773 was modified to TCA by site-
directed mutagenesis and homologous substitution of the NarI-BsrGI-mutated
segment (nucleotides 2046 to 2536). Sequence analysis was carried out to verify
the sequence of the substituted segment. The resulting plasmid was named
pT7-B-HDR.
Construction of pT7-A-HDR derivatives. The mutations were introduced by
using the Pfu DNA polymerase with the QuickChange site-directed mutagenesis
kit (Stratagene) as described by the manufacturer. Nucleotide sequence analyses
were carried out to confirm nucleotide substitutions. The corresponding DNA
stretch defined by restriction sites Eco52i (nucleotide 1291) and NruI (nucleotide
1689) was excised and subcloned into pT7-A-HDR restricted by Eco52i and
NruI. Next, pT7-A-HDR derivatives were validated by sequence analysis of the
complete [Eco52i-NruI] insert using the primers 5-GGTGAGCAACTTCGAG
CTGATCCCA and 5-ACTGAGTGAGAGGGACCGTCTTG.
Generation of recombinant viruses. To generate infectious IBDV from cDNA
clones, a strategy similar to that previously described by Boot et al. (5) was used.
For virus rescue experiments, we used the primary hepatocellular carcinoma
epithelial cell line LMH (12) or the quail pectoralis fibrosarcoma cell line QT6
(17) grown in RPMI medium supplemented with 10% Fetal calf serum, 1%
chicken serum, 2 mM glutamine, and 1 mM sodium pyruvate and complemented
with tryptose phosphate broth (Gibco-BRL) for QT6 cells. Cells at 90% conflu-
ence in P12 wells were infected with MVA-T7 (27) at a multiplicity of infection
of 1. After a 1-h adsorption, the cells were rinsed with the RPMI medium. In the
meantime, pT7-A-HDR derivatives and pT7-B-HDR were mixed (0.5 g for
each plasmid) with 3.5 l of LipofectAMINE (GIBCO-BRL) in 350 l of
OptiMEM and were kept at room temperature for 30 min. The cells were again
rinsed in OptiMEM and incubated with the DNA-LipofectAMINE mixture at
37°C for 5 h. Subsequently, 0.5 ml of OptiMEM was added to the cells for
overnight incubation. Next, 1.5 ml of complemented RPMI medium was added
to each well. Recombinant mutant viruses were recovered 48 or 72 h posttrans-
fection after filtration through a 0.22-m-pore-size filter. At least four indepen-
dent transfection experiments were carried out to analyze each pT7-A-HDR
derivative. The viruses were amplified on LSCC-BK3 cells, a B-lymphoid cell line
highly permissive for IBDV (25).
FACS analysis. IBDV-infected LSCC-BK3 cells were analyzed 3 or 5 days
postinfection. Briefly, the cells were fixed with 2.5% paraformaldehyde in phos-
phate-buffered saline for 30 min at room temperature and permeabilized by
incubation for 10 min in 0.1% Triton X-100. Fixed cells were incubated with a
1:250 dilution of an anti-VP3 monoclonal antibody. Next, the cells were rinsed
and incubated with an anti-immunoglobulin mouse fluorescein isothiocyanate
conjugate in phosphate-buffered saline–0.05% Tween. The cells were rinsed
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three times and subjected to FACScan (Becton Dickinson) analysis using the
Cell Quest software.
RESULTS
Identification of several IBDA polyprotein-derived peptides
as components of the IBDV virions. VP2, one of the protein
capsids of IBDV, arises from pVP2 through proteolytic pro-
cessing. To gain information on the maturation of pVP2, we
investigated the possible presence in the viral particles of
pVP2-derived peptides. IBDV particles were purified by den-
sity gradient centrifugation. Three main bands were observed
in the gradient (Fig. 5, in the accompanying paper [6a]). All the
bands displayed virus particules when analyzed by electron
microscopy, and they displayed the structural proteins VP1,
VP2, and VP3 when analyzed by SDS-PAGE. It should be
noted that type I and type II tubules, made of pVP2 and VP4,
respectively (10), were not revealed by electron microscopy in
our preparations. Experiments were first carried out with the
material present in the lower band; other bands gave similar
results. In addition to the capsid proteins, we identified a
polypeptide with a relative mass of about 5 kDa by using
SDS-PAGE (16% polyacrylamide) (Fig. 1A). The first 15
amino acids of the polypeptide were determined through N-
terminal sequencing: NH2-Phe-Gly-Phe-Lys-Asp-Ile-Ile-Arg-
Ala-Leu-Arg-Arg-Ile-Ala-Val-COOH. This sequence was
identical to the IBDA polyprotein sequence starting at Phe-
442. To investigate the presence of this peptide, mass spec-
trometry analysis was carried out on the viral particles. A
peptide with an [MH] mass (23) of 4,874.72 Da was indeed
detected (Fig. 1B). No other peptide with the same mass range
was detected. This [M  H] mass fits well the mass of a
peptide extending from Phe-442 to Ala-487, which is 4,874.67
Da.
Another peptide with an [M  H] mass of 1,185.70 Da was
also revealed (Fig. 1B). To purify the peptide from the virus
particle preparations, we performed HPLC purification (data
not shown). Two major peaks were detected. Mass spectrom-
etry was carried out on each fraction. A peptide with a mass of
1,185.82 Da eluted in the first peak. The complete sequence of
this peptide was determined as NH2-Ala-Ser-Gly-Arg-Ile-Arg-
Gln-Leu-Thr-Leu-Ala-COOH. This sequence was identical to
the IBDA polyprotein sequence from residues 502 to 512.
Since cleavage at the pVP2-VP4 junction occurs between
amino acids 512 and 513, this peptide is indeed the C terminus
of pVP2. Note that the theoretical [M  H] mass of this
peptide was 1,185.71 Da, fitting well with its experimental
determinations. The second peak that eluted from the gradient
had a mass of 28,791 Da and corresponded to VP3.
The presence of the two peptides from residues 442 to 487
([442–487]) and from 502 to 512 ([502–512]) in the viral par-
ticles prompted us to locate a putative peptide(s) deriving from
the 14-amino-acid sequence extending from residues 488 to
501 (Fig. 2A). The sequence surrounding the two alanines at
positions 494 and 495 had a strong homology to the cleavage
sites identified at positions 487–488 and 501–502, thus suggest-
ing the possible generation of two 7-amino-acid peptides. To
identify the putative peptide(s), we carried out an N-terminal
sequencing on the purified virus. Because the main capsid
proteins VP2 and VP3 were reported to be blocked (9), only
peptides were expected to be sequenced. The results are pre-
sented in Fig. 2B. Large numbers of Ala, Ser, and Gly residues
were revealed at positions 1, 2, and 3, a sequence which was
present at the N terminus of peptide [502–512] but also at the
N terminus of the two putative 7-amino-acid peptides. Impor-
tantly, the sequence Thr-Ala-Arg-Ala was identified at posi-
tions 4 to 7, thus demonstrating the presence of an additional
peptide with an N terminus at position 488. No Ala, Ser, or Gly
residues were detected at positions 8, 9, or 10, respectively,
showing that the 7-amino-acid peptides were analyzed. Our
results demonstrated that the viral particles contain the pep-
tide extending from residues 488 to 494. The presence of the
fourth peptide mapping from residues 495 to 501 inside the
viral particles was not demonstrated, since each of its amino
acids was redundant with a residue present in the three other
peptides; however, its presence cannot be ruled out. Finally, we
also observed that the N terminus of the VP2 protein was only
partially blocked, allowing identification of the N terminus of
VP2 as the Thr immediatly following the Met initiation codon.
FIG. 1. Characterization of peptides present in IBDV particles. (A) SDS-PAGE (16% polyacrylamide) analysis of purified virus. A peptide of
about 5 kDa was identified and excised from the gel for N-terminal sequence analysis. Its N terminus was mapped at residue 442. Molecular mass
markers are indicated on the left. (B) Mass spectrometry analysis of IBDV particles. Two main signals were identified on the mass/charge window
ranging from 935 to 4,996. Magnified signals showing the isotopic pattern are inserted. The [M  H] values for the peptides are 1,185.7 and
4,874.7 Da, respectively.
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In conclusion, at least three (probably four) peptides, which
correspond to amino acid stretches 442 to 487, 488 to 494, 495
to 501, and 502 to 512, were detected in viral particles. Note
that the three shorter peptides have sequence identity: all of
them have (i) the triplet Ala-Ser-Gly at their N termini, (ii) an
Ala residue at their C termini, and (iii) generally positively
charged residues at positions 4 and 6 (Fig. 2).
Identification of several IBDA polyprotein-derived peptides
as components of the IBDV VLPs. We showed that the final
maturation process converting pVP2 into the mature form of
VP2 occurs during the generation of virus-like particles
(VLPs) in the baculovirus expression system (6a). We there-
fore carried out a mass spectrometry analysis on VLPs. Three
peptides, with [M  H] masses of 1,185.6, 4,875.7 and 5,491.0
Da, were detected (Fig. 3). The first two peaks were identical
to those identified on virions and corresponded to the [442–
487] and [502–512] peptides. This result showed that the pro-
cessing is similar in the virus and in VLPs, although not iden-
tical, as shown by the presence of a third peak. The mass of the
third peak (5,491.0 Da) corresponded to the sum of the masses
of the [442–487] and [488–494] peptides minus the mass of a
water molecule (4874.67  632.32  18.01). These results
suggested that the kinetics of pVP2 maturation is slower dur-
ing VLP formation than for virions.
The amino acid stretch from 442 to 512 constitutes the
pVP2-specific domain. The existence of the four peptides sug-
gests that the amino acid stretch from 442 to 512 represents the
domain which is processed during pVP2 maturation. To deter-
mine if the pVP2-processed domain involves residus upstream
of residue 441, we engineered a construct driving expression of
the polyprotein with a stop codon at position 442 to compare
the electrophoretic mobility of the mature VP2 with this trun-
cated form. Because pVP2 processing is not observed in the in
vitro expression system, full-size protein production was ex-
pected under these conditions. As shown in Fig. 4, the mature
VP2 and the in vitro-expressed VP2-stop442 comigrated, sug-
gesting that the pVP2 characteristic domain does not extend
upstream of residue 441.
Effect of mutations at the pVP2 cleavage sites. To study the
pVP2 processing, we constructed a reverse genetic system.
Engineered plasmids pT7-A-HDR and pT7-B-HDR were con-
structed as described in Materials and Methods. Cotransfec-
tions of these plasmids into T7 polymerase-expressing cells
resulted in the production of a viable virus. We analyzed the
FIG. 2. N-terminal sequencing of the purified virus. (A) Sequence of the pVP2-specific domain from amino acids 442 to 512. The single-letter
code is used to indicate amino acids. Arrows indicate the cleavage sites. (B) The nature of the amino acids and the amount (differential picomoles)
revealed at each Edman degradation cycle (amino acid position) are indicated. Sequences of the peptides (and of the mature VP2) have been
aligned on the identified residues. Residues which are potentially present in more than one peptide are indicated in italics.
2396 DA COSTA ET AL. J. VIROL.
 at LAN
D
BO
UW
UNIVERSITEIT on Septem
ber 25, 2008 
jvi.asm.org
D
ow
nloaded from
 
effects of amino acid substitutions at the P1 and P1 positions
of each cleavage site. Two groups of mutants characterized by
double or single substitutions were constructed (Fig. 5). The
first group was made up of eight mutants in which the P1 and
the P1 residues were replaced by Glu and Phe, respectively.
The second group was made up of 18 point mutants to analyze
amino acid specificity at the P1 or P1 positions of the pVP2-
VP4 cleavage site (position 512–513) and the VP2 maturation
cleavage site (position 441–442).
With the first group of mutants, the viruses were consistently
obtained on transfection with the pT7-A-HDR derivatives
A487E/A488F, A494E/A495F, and A501E/A502F (Fig. 5). No
virus was recovered in the cells transfected with the A512E/
A513F plasmid or with plasmids harboring cumulative double
substitutions engineered at two pVP2 cleavage sites.
Viral growth of the three viable mutants was quantified by
performing a plaque assay (Fig. 6A) and by measuring virus
production at 3 days postinfection (Fig. 5). While the mutant
viruses A487E/A488F and A501E/A502F showed wild-type
growth characteristics, virus A494E/A495F produced only 10
to 20% of the amount of the wild-type virus and displayed a
small-plaque phenotype. pVP2 processing was also studied by
SDS-PAGE for all mutants. Figure 6B shows the VP2 band
pattern in infected cells and in their cell medium. These mu-
tations modulated the processing of pVP2. For instance,
whereas two faint bands of cleaved pVP2 forms were observed
with the wild-type virus, a unique main cleaved pVP2 form was
identified with the virus A487E/A488F. To quantify the effi-
ciency of the pVP2-to-VP2 conversion, autoradiograms were
subjected to densitometry. The ratio between the pVP2 and
mature VP2 was not significantly modified in these mutants.
To analyze the cleavage specificity, point mutations were
engineered at the pVP2-VP4 cleavage site (position 512–513)
and at the VP2 maturation cleavage site (position 441–442)
(Fig. 5). For these sites, no substitution was tolerated in gen-
eral at the P1 or P1 position. However, replacements of Ala-
512 and Ala-513 by Gly allowed virus recovery. The Ala-
513Gly mutant even appeared to replicate better than the wild
type in terms of rescue efficiency and virus production (Fig. 5).
The in vitro processing of the different engineered polyprotein
mutants at position 512–513 was then analyzed, and the results
correlated with those of the rescue experiments. With the
Ala512Gly and Ala513Gly substitutions, cleavage occurred ef-
ficiently, at the right position (Fig. 7). Small amounts of
cleaved forms of pVP2 were nevertheless observed with the
Ala512Gly mutant. In contrast, all other substitutions resulted
in the generation of smaller forms of pVP2. In conclusion,
rescue efficiency and correct cleavage at the pVP2-VP4 junc-
tion were well correlated. Note, that as already mentioned for
the Ala512Glu-Ala513Phe mutant (14), VP4 was no longer
detectable in in vitro expression assays when the cleavage be-
tween pVP2 and VP4 was incorrect.
Effect of deletions of peptides [442–487], [488–494], [495–
501], and [502–512]. To investigate the importance of peptides
[442–487], [488–494], [495–501], and [502–512] in the virus
cycle, we constructed mutants with one of these peptides de-
leted (Fig. 8). The virus was consistently recovered on trans-
fection of cells with pT7-A-delta[488–494]-HDR or pT7-A-
delta[495–501]-HDR in our reverse genetic system. However,
these deletions led to a small-plaque phenotype (Fig. 6A). The
FIG. 3. Mass spectrometry analysis of IBDV VLPs. Three main signals were identified in the mass/charge window. Magnified signals showing
the isotopic pattern are inserted. The [M  H] values for the peptides are 1,185.6, 4,875.7 and 5,491.0 Da, respectively.
FIG. 4. Comparison of the electrophoretic mobilities of the differ-
ent forms of VP2. Mock-infected () or IBDV-infected [IBDV(CT)]
cells were 35S labeled and subjected to immunoprecipitation with an
anti-VP2 monoclonal antibody. Denatured immune complexes were
run side by side on an SDS-PAGE gel with an in vitro translation
product of the mutated IBDA polyprotein having a stop codon at
position 442 (VP2/1–441). The gel was subjected to autoradiography.
Molecular mass markers are indicated on the left.
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processing of the deleted pVP2s was analyzed by radioimmu-
noprecipitation and SDS-PAGE. The ratio between the pVP2s
and the VP2 mature forms was not significantly modified with
these deletion mutants (data not shown). When pT7-A-del-
ta[442–487]-HDR or pT7-A-delta[502–512]-HDR was trans-
fected, the virus was not recovered through our reverse genetic
system. These results demonstrate the importance of the [442–
487] and [442–487] peptides in the virus cycle.
Effects of point mutations in the [488–494], [495–501], and
[501–512] domains. The point mutations in the two peptides
[488–494] and [495–501] did not prevent virus rescue in our
reverse genetic system, which is in agreement with the fact that
deletions of these domains did not strongly affect virus recov-
ery (Fig. 8). Most point mutations in the [502–512] domain
were lethal, which is in agreement with the fact that the dele-
tion of the domain did not allow virus rescue. The in vitro
polyprotein processing of the lethal mutants was then ana-
lyzed. The mutations did not inactivate the cleavage site at the
pVP2-VP4 junction (data not shown). These results confirmed
the importance of the [502–512] peptide and particularly the
amino acid stretch from residues 504 to 509.
DISCUSSION
The first step of the IBDV polyprotein processing is its
autocatalytic cleavage by the VP4 viral protease to generate
pVP2, VP4, and VP3. Cleavage at the pVP2-VP4 junction
occurs between two alanines located at positions 512 and 513
(14, 20). The main objective of this study was to delineate the
maturation process of pVP2.
In this study, we identified at least three (most probably
four) peptides derived from the pVP2-specific domain and
showed that these peptides are associated with the viral parti-
cles. Their presence in the viral particles was revealed using
different biochemical approaches, including N-terminal se-
quencing and mass spectrometry. These peptides were made
up of different amino acid stretches, 442 to 487, 488 to 494, 495
to 501, and 502 to 512, and, together, they defined the domain
associated with the cleavage maturation of pVP2.
We also developed a reverse genetic approach to examine
the importance of these peptides in the virus cycle. First, we
tried to rescue mutants in which one of the four peptides was
deleted. Deletions of the amino acid stretches from 488 to 494
and from 495 to 501 did allow production of infectious virus,
even though these mutants appeared to replicate less efficiently
than the wild-type. Substitutions at different positions of these
two peptides were found to be permissive for virus replication.
These results showed that these two peptides with nearly iden-
tical sequences have the same, but accessory, function in the
virus cycle.
In contrast, deletions of the amino acid stretches from 442 to
487 and from 502 to 512 did not allow the rescue of infectious
virus. The importance of the [502–512] peptide was also dem-
onstrated by site-directed mutagenesis. Each of the six residues
of the amino acid stretch from 504 to 509 was shown to be
essential for virus recovery. Further experiments are neverthe-
FIG. 5. Virus recovery for the pVP2 cleavage site mutants. The amino acid sequence of the pVP2-specific domain and the different cleavage
sites (arrows) are indicated at the top of the figure. The mutated amino acid(s) is indicated for each construct in the single-letter code. Depending
on the virus recovery results, the plasmids are indicated by a  (recovery) or  (nonrecovery). The relative plaque size at 48 h after infection of
confluent LMH cell monolayers is indicated. wt, wild-type size; small, smaller than wild-type size. Rescued viruses were amplified on LSCC-BK3
cells, and virus titers were determined 3 days postinfection on LMH cells.
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less needed to address the contribution of these two peptides
to the assembly process of the virus particles or other critical
steps of the virus cycle.
The presence in infected cells of cleaved forms of pVP2 with
higher mobilities than pVP2 in gel electrophoresis suggested
that the trimming of pVP2 to VP2 was directional and involved
a cascade of proteolytic cleavages starting at the COOH ter-
minus of pVP2 progressing toward the final maturation cleav-
FIG. 6. Phenotypes of several mutants. (A) Typical aspect of plaques formed by the indicated mutants. The dilutions used for the assay are
indicated. (B) Analysis of the pVP2 processing in cells infected with the indicated mutants. Left lanes show VP2 immunoprecipitations of the cell
extracts; right lanes show VP2 immunoprecipitations of the cell supernatants. In the middle is shown mature VP2 (VP2/1–441) expressed in vitro.
IBDV (CT) indicates the results of a regular (nonrescued) infection. Lane A512E-A513F, no rescued virus with the corresponding plasmid.
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age site at position 441–442. Four target cleavage sites were
involved in the pVP2 maturation process. We previously pro-
posed three of them (501–502, 494–495, and 487–488) as tar-
gets of the VP4 protease (14). These sites with the primary
cleavage at the pVP2-VP4 junction were defined by the motif
(T/A)XA2A. This consensus sequence shared some homology
to the sequence AGA2F surrounding the maturation cleavage
site at position 441–442, suggesting that VP4 was probably
involved in the last cleavage, generating the mature VP2. How-
ever, it cannot be definitively ruled out that another protease
(cellular or virus encoded) may cleave at this position. The fact
that the Phe442Gly substitutions do not allow virus replication,
in contrast to what is observed with the Ala513Gly substitution,
provides some support for this hypothesis.
Several lines of evidence support the view that these pep-
tides have homologs in other birnaviruses (Fig. 9A). (i) The
pVP2 sequences of different birnaviruses (infectious pancre-
atic necrosis virus and Drosophila X virus) have strong simi-
larities, mainly in the [442–487] peptide. In the short peptides,
a basic residue is often identified at positions 4 (and 6). (ii) the
IBDV cleavage site motif [T/A]XA2A has homologs in infec-
tious pancreatic necrosis virus ([S/T]XA2A) (18) and in Dro-
sophila X virus ([A/G]XS2A) (8). (iii) The sequences sur-
rounding the final maturation cleavage site at position 441–442
have sequence similarity. It should also be noted that for in-
fectious pancreatic necrosis virus and Drosophila X virus, only
three peptides have been predicted. Preliminary experiments
carried out on purified infectious pancreatic necrosis virus
agreed with this prediction (data not shown). We concluded
that the pVP2 maturation is a characteristic process of birna-
viruses.
In nodaviruses, another family of nonenveloped viruses, the
maturation of the viral particles generates the mature coat
protein beta (363 residues) and the gamma peptide (44 resi-
dues). This peptide plays a key role in the passage of the viral
genomic material through the cell membrane. Indeed, while its
C-terminal region drives specific packaging of the genomic
RNA (22), the N-terminal region could alter membrane struc-
ture and then mediate the translocation of the viral genome (3,
FIG. 7. In vitro processing of different P1 or P1 mutants. The
autoradiograph shows the results obtained with pT7-IBDA-HDR (wt)
and a set of P1 or P1 mutants produced in a rabbit reticulocyte
expression system. Expression products were analyzed by SDS-PAGE
(10% polyacrylamide), and the gel was processed for autoradiography.
The positions of the viral polypeptides are indicated on the right.
FIG. 8. Virus recovery of the pVP2 mutants. The amino acid sequence of the pVP2-specific domain and the different cleavage sites (arrows)
are indicated at the top of the figure. Deleted amino acids are indicated by an asterisk, and substitutions are indicated for each plasmid in the
single-letter code. Depending on the virus recovery results, the plasmids are indicated by  (recovery) or  (nonrecovery). Plaque size and virus
production were analyzed as described in the legend to Fig. 5.
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11). Structural and biophysical information showed that the
gamma N-terminal domain forms an -helix inside the virus
particle and lipid bilayer but adopts a random-coil structure in
aqueous solution (4, 26). As with nodaviruses, the N-terminal
half of the [442–487] peptide could form an -amphipathic
helix, as shown in Fig. 9B. We could therefore speculate that
this peptide played a role in RNA-packaging specificity and in
the disruption of the endosomal membrane during virus entry
into the target cell.
In conclusion, we have shown for the first time that viral
capsids contain short peptides (7 to 46 residues long) that are
derived from the maturation processes of their structural pro-
teins. These peptides may play a crucial role in capsid assem-
bly, genome encapsidation, and genome entry into the target
cell.
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